Payment overview · 2025
General Payments
$1,010.16
59 reported records · 17 companies
Healthcare provider profile · identity verified
Peter Souheil Haddad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, TX · NPI 1033644299
Verified facts
What the public records show
CMS Open Payments records show Peter Souheil Haddad, M.D. received $1,010.16 in general payments during 2025 across 59 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Xifaxan.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $169.77 | 16.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.16 | 14.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.69 | 13.5% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $100.52 | 9.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $91.83 | 9.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.50 | 7.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.17 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.72 | 5.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.20 | 3.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.98 | 2.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.11 | 2.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.84 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.57 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.87 | 1.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.74 | 1.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $13.49 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,010.16 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $169.77 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $136.69 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $136.69 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.82 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100.52 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $91.83 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.50 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.17 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $51.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $27.98 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 66 |
| Furosemide | Furosemide | 315 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 67 |
| Sertraline Hcl | Sertraline Hcl | 261 | 36 |
| Losartan Potassium | Losartan Potassium | 255 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 51 |
| Gabapentin | Gabapentin | 194 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 44 |
| Lisinopril | Lisinopril | 183 | 52 |
| Buspirone Hcl | Buspirone Hcl | 173 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 27 |
| Eliquis | Apixaban | 137 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 60 |
| Trazodone Hcl | Trazodone Hcl | 133 | 28 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 41 |
| Famotidine | Famotidine | 122 | 25 |
| Potassium Chloride | Potassium Chloride | 118 | 35 |
| Meloxicam | Meloxicam | 106 | 33 |
| Carvedilol | Carvedilol | 105 | 25 |
| Baclofen | Baclofen | 104 | suppressed |
| Simvastatin | Simvastatin | 100 | 19 |
| Spironolactone | Spironolactone | 99 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 27 |
| Jardiance | Empagliflozin | 92 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 24 |
| Azelastine Hcl | Azelastine Hcl | 84 | 44 |
| Omeprazole | Omeprazole | 84 | 18 |
| Ozempic | Semaglutide | 81 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 21 |
| Donepezil Hcl | Donepezil Hcl | 76 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 14 |
| Clonidine Hcl | Clonidine Hcl | 71 | 20 |
| Mounjaro | Tirzepatide | 70 | suppressed |
| Klor-Con M20 | Potassium Chloride | 69 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | suppressed |
| Allopurinol | Allopurinol | 57 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 31 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Mirtazapine | Mirtazapine | 43 | 17 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 32 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 13 |
| Lactulose | Lactulose | 32 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 21 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Doxepin Hcl | Doxepin Hcl | 26 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 17 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 18 |
| Glipizide | Glipizide | 23 | suppressed |
| Prednisone | Prednisone | 23 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 11 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,010.16 · 59 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, AUSTEDO XR, Cologuard Collection Kit, FARXIGA, INSPIRE, Kerendia, LEQVIO, LOREEV XR, MOUNJARO, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TZIELD, VYNDAQEL, Veozah, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error